Journal Logo

Poster Session I: Indolent and mantle-cell non-Hodgkin lymphoma – Clinical

PF487 MAJOR RESPONSES IN MYD88 WILDTYPE (MYD88WT) WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH BRUTON TYROSINE KINASE (BTK) INHIBITOR ZANUBRUTINIB (BGB-3111)

Dimopoulos, M.1; Opat, S.2,3; Lee, H.-P.4; Cull, G.5,6; D'Sa, S.7; Owen, R.8; Tedeschi, A.9; García Sanz, R.10; Varettoni, M.11; Buske, C.12; LeBlond, V.13; Chan, W.Y.14; Schneider, J.14; Osman, M.14; Cohen, A.14; Huang, J.14; Tam, C.S.15,16,17,18

Author Information
doi: 10.1097/01.HS9.0000560248.83366.72
  • Free

Abstract

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.